CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Novocure Q3 net loss narrows 72% to USD 10.44 million

By Public Technologies
  • Novocure’s third-quarter 2026 net loss narrowed 72% year over year to $10.44 million.
  • Net revenues rose 16% year over year to $193.4 million, driven by 19% growth in global active patients.
  • Optune Pax secured Japanese approval in October for adults with unresectable locally advanced pancreatic cancer, alongside gemcitabine and nab-paclitaxel.
  • Full-year 2026 net revenues guidance increased to $736 million–$743 million from $710 million–$725 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610290700BIZWIRE_USPR_____20261029_BW363518) on October 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk